Monitoring Giant Cell Arteritis During Treatment Tapering
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tracks patients with giant cell arteritis (GCA, a blood vessel inflammation affecting older adults) who are in remission and tapering their steroid medications. Researchers will monitor disease activity through blood tests and patient questionnaires to understand if their condition stays stable as they reduce treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with GCA by a rheumatologist with confirmed imaging or biopsy within the past 3 years
- Currently in remission: on stable or tapering steroids for at least 8 weeks with no worsening GCA symptoms
- Normal inflammation blood test (CRP < 10 mg/L) within the past week
- Age 50 or older
- Able to speak, read, and understand Danish
- Able to complete online questionnaires and commit to ongoing monitoring during medication tapering
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses ultrasound, a biopsy of the temple artery, and blood tests to improve how giant cell arteritis (GCA) is diagnosed, monitored, and predicted. It may help doctors find better ways to manage this condition.
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
This trial compares two different lengths of steroid treatment for giant cell arteritis, an inflammatory blood vessel disease. Participants receive the medication tocilizumab along with either 8 weeks or 26 weeks of prednisone, to see if a shorter course is just as safe and effective.
This study tracks how quickly your C-reactive protein (CRP) level, a marker of inflammation, drops after you start taking steroids (glucocorticoids) for giant cell arteritis. The goal is to find better ways to monitor treatment response in this condition.
This study looks at immune cells called B-cells in people with giant cell arteritis (a condition causing inflammation in blood vessels) and other immune disorders, to see if targeting these cells could be a new treatment. It involves imaging and blood tests.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
Hear when a new Giant Cell Arteritis (GCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.